Lexicon Pharmaceuticals (LXRX) Financials: History & Chart

Lexicon Pharmaceuticals, Inc.(LXRX)

Biotechnology · The Woodlands, TX

$1.75+0.01 (+0.29%)

Delayed quote: Oct 6, 2026, 12:35 PM EDT

About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

The Woodlands, TX

81 employees

www.lexpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael S. Exton

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	41.47M	692K	21.10M	5.49M	14.18M	28.87M	1.26M	26.55M	1.75M
Cost of Goods Sold	476K	39K	108K	319K	10K	209K	30K	25.93M	71K
Gross Profit	40.99M	653K	20.99M	5.17M	14.17M	28.66M	1.23M	621K	1.68M
Gross Profit Margin	98.9%	94.4%	99.5%	94.2%	99.9%	99.3%	97.6%	2.3%	95.9%
Total Operating Expenses	95.50M	27.19M	21.99M	19.95M	26.36M	24.92M	26.91M	33.36M	65.37M
Research & Development	60.15M	17.44M	12.76M	11.20M	18.76M	15.57M	15.30M	26.68M	25.78M
Selling, General & Administrative	35.34M	9.75M	9.23M	8.76M	7.60M	9.35M	11.61M	0.00	39.59M
Operating Income (EBIT)	-54.50M	-26.54M	-996K	-14.78M	-12.19M	3.74M	-25.68M	-32.74M	-63.69M
Operating Margin	-131.4%	-3835.3%	-4.7%	-269.1%	-85.9%	12.9%	-2034.8%	-123.3%	-3639.6%
Income Before Tax (EBT)	-61.12M	-31.77M	-1.04M	-15.53M	-12.77M	3.25M	-25.30M	-33.77M	-64.81M
Interest Income	6.12M	1.72M	1.54M	1.28M	1.57M	1.83M	2.22M	2.83M	3.44M
Interest Expense	8.38M	2.61M	1.59M	2.03M	2.15M	2.32M	1.83M	3.86M	4.56M
Other Income/Expense	-6.61M	-5.24M	-47K	-750K	-582K	-484K	384K	-1.03M	-1.12M
Net Income	-61.12M	-31.77M	-1.04M	-15.53M	-12.77M	3.25M	-25.30M	-33.77M	-64.81M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-147.4%	-4591.8%	-4.9%	-282.7%	-90.0%	11.3%	-2004.4%	-127.2%	-3703.5%
EBITDA	-54.02M	-26.44M	-886K	-14.66M	-12.04M	3.91M	-25.50M	-32.61M	-63.57M
EBITDA Margin	-130.3%	-3820.5%	-4.2%	-266.9%	-84.9%	13.6%	-2020.8%	-122.8%	-3632.4%
Depreciation & Amortization	481K	102K	110K	118K	151K	176K	176K	125K	126K
EPS Basic	-0.15	-0.07	-0.00	-0.04	-0.04	0.01	-0.07	-0.09	-0.18
EPS Diluted	-0.15	-0.07	-0.00	-0.04	-0.04	0.01	-0.07	-0.09	-0.18
Weighted Average Basic Shares	437.65M	437.65M	400.24M	363.43M	363.40M	363.29M	362.07M	361.49M	361.49M
Weighted Average Diluted Shares	437.65M	437.65M	400.24M	363.43M	363.40M	363.57M	362.07M	361.49M	361.49M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	49.80M	31.08M	1.20M	139K	298K	24.00M	322.07M	63.21M
Cost of Goods Sold	274K	616K	58.97M	52.52M	55.05M	1.93M	3.23M	2.49M
Gross Profit	49.53M	30.46M	-57.77M	-52.38M	-54.75M	22.07M	318.84M	60.72M
Gross Profit Margin	99.4%	98.0%	-4798.0%	-37681.3%	-18371.8%	92.0%	99.0%	96.1%
Total Operating Expenses	98.44M	227.58M	113.98M	48.38M	32.34M	69.87M	177.40M	164.00M
Research & Development	61.12M	84.48M	58.89M	52.82M	55.05M	153.62M	91.92M	100.24M
Selling, General & Administrative	37.32M	131.90M	0.00	0.00	0.00	47.23M	56.84M	63.75M
Operating Income (EBIT)	-48.91M	-197.12M	-171.75M	-100.76M	-87.09M	-47.80M	141.44M	-103.28M
Operating Margin	-98.2%	-634.2%	-14265.0%	-72489.2%	-29224.8%	-199.2%	43.9%	-163.4%
Income Before Tax (EBT)	-50.34M	-200.40M	-177.12M	-101.94M	-87.76M	-58.57M	124.12M	-120.55M
Interest Income	6.91M	12.29M	7.73M	1.60M	134K	2.77M	3.35M	3.51M
Interest Expense	8.34M	15.58M	13.10M	2.78M	802K	14.54M	20.68M	20.78M
Other Income/Expense	-1.43M	-3.29M	-5.37M	-1.18M	-668K	-10.77M	-17.33M	-17.27M
Net Income	-50.34M	-200.40M	-177.12M	-101.94M	-87.76M	-58.57M	130.13M	-120.55M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	-6.01M	0.00
Net Profit Margin	-101.1%	-644.8%	-14710.9%	-73341.0%	-29449.0%	-244.1%	40.4%	-190.7%
EBITDA	-48.29M	-196.58M	-171.20M	-100.33M	-86.80M	-44.87M	145.10M	-99.60M
EBITDA Margin	-97.0%	-632.5%	-14218.9%	-72182.0%	-29126.8%	-187.0%	45.1%	-157.6%
Depreciation & Amortization	621K	534K	554K	427K	292K	2.93M	3.65M	3.68M
EPS Basic	-0.14	-0.63	-0.80	-0.62	-0.61	-0.63	1.23	-1.14
EPS Diluted	-0.14	-0.63	-0.80	-0.62	-0.61	-0.63	1.11	-1.14
Weighted Average Basic Shares	363.05M	320.03M	221.13M	165.73M	145.65M	110.84M	106.22M	105.74M
Weighted Average Diluted Shares	363.05M	320.03M	221.13M	165.73M	145.65M	110.84M	116.75M	105.83M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.